Abstract
Cardiovascular (CV) disease is the most common cause of mortality among kidney transplant candidates on the waiting-list and after kidney transplantation. The mechanisms of cardiovascular disease burden after transplant are multifactorial and the risk is largely determined by pre-transplant factors including CV disease and dialysis duration. Current pre-transplant cardiac evaluation protocols have proven to be inconsistent in predicting adverse cardiovascular outcome post-transplant. However, multiple biomarkers have been recognized as predictors of all-cause mortality and cardiovascular events including graft function, hemoglobin, homocysteine, C - reactive protein among others. Of these, elevation in the biomarker cardiac troponin T appears to be a significant predictor of cardiovascular events and mortality among wait-listed kidney transplant candidates and after transplantation. The relationship between CV risk reduction, normalization of cardiac troponin T levels and restoration of renal function after kidney transplant is complex but opens opportunities for the use of cardiac troponin T and other cardiovascular biomarkers as important endpoints of clinical interventions in kidney transplant recipients.
Original language | English (US) |
---|---|
Pages (from-to) | 185-194 |
Number of pages | 10 |
Journal | Cardiovascular and Hematological Disorders - Drug Targets |
Volume | 14 |
Issue number | 3 |
DOIs | |
State | Published - Jan 1 2014 |
Keywords
- Cardiovascular disease
- Kidney transplant
- Risk factors
ASJC Scopus subject areas
- Molecular Medicine
- Hematology
- Pharmacology
- Cardiology and Cardiovascular Medicine